Pulmonary Tuberculosis and Risk of Lung Cancer: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Infectious Diseases | Public, Environmental & Occupational Health | Respiratory System
Contributor:
Lee Kyoung Hwa

Lung cancer accounts for approximately 18.4% of the total cancer-related deaths, the highest of all cancer types. The prognosis of lung cancer is relatively unfavorable compared to that of other malignancies, and as a prognosis largely depends on the stage of onset, thus, the early diagnosis of lung cancer is very important. Pulmonary tuberculosis (TB) is a known risk factor for lung cancer.

  • pulmonary tuberculosis
  • lung cancer

1. Introduction

Chronic inflammation resulting in pathological changes is a major risk factor in carcinogenesis. Inflammation is known to play a key role in carcinogenesis, such as infection with hepatitis B and C viruses in hepatocellular carcinoma, Helicobacter pylori in gastric cancer, and human papilloma virus in gynecological cancers [1]. Several meta-analyses have shown that previous inflammatory diseases in the lungs, such as pneumonia, chronic bronchitis, and pulmonary tuberculosis (TB), may increase the risk of lung cancer (relative risk ratio 1.36–1.90), independent of cigarette smoking [2][3]. According to forty-nine studies, pulmonary and extra-pulmonary TB infections increase the risk of 10 cancer types, including head and neck cancer, leukemia, lymphoma, gastrointestinal cancer, kidney cancer, bladder cancer, and lung cancer [4]. Thus, TB infection may influence the pathogenesis of lung cancer with or without cigarette smoking. To prevent the emergence of airborne transmittable TB and its progression to cancer, the control and prevention of TB is very important.

2. Pulmonary TB and Risk of Lung Cancer with All Eligible Studies

The overall association between a previous history of pulmonary TB and newly diagnosed lung cancer was statistically significant (odds ratio (OR): 2.09; 95% confidence interval (CI): 1.62–2.69, p < 0.001). There was high heterogeneity (I2 = 95%), no evidence of publication bias, the egger p-value was 0.447, and no visual asymmetry in the funnel plot (Figure 1A and Figure 2A). In the subgroup analysis by TB burden, the high-burden countries showed higher OR (2.57, 95% CI: 1.68–3.93, p < 0.001) than the medium-burden (OR: 2.48, 95% CI: 1.71–3.58, p < 0.001) and low-burden countries (OR: 1.77, 95% CI: 1.22–2.56, p = 0.003). Geographically, East Asia and the Pacific region showed a prominent risk (OR: 2.49, 95% CI: 1.83–3.39, p < 0.001) compared to the Europe and Central Asia (OR: 1.60, 95% CI: 0.80–3.22, p = 0.185) or North America (OR: 1.53, 95% CI: 1.11–2.12, p = 0.010) regions. The economic income statuses of the countries also reflected the characteristics of patients with TB, and the countries with upper-middle incomes (OR: 2.57, 95% CI: 1.68–3.93, p < 0.001) demonstrated a higher risk of lung cancer than high-income status countries (OR: 1.91, 95% CI: 1.41–2.59, p < 0.001). The association between pulmonary TB and newly developed lung cancer was statistically significant regardless of the adjustment for age, sex, smoking status, and cohort type or study design. The magnitude of association was similar regardless of whether pulmonary TB was diagnosed based on medical records (OR: 2.26, 95% CI: 1.29–3.94, p = 0.004), imaging (OR: 2.13, 95% CI: 1.16–3.92, p = 0.015), or self-report/physical examination (OR: 1.96, 95% CI: 1.56–2.47, p < 0.001). The heterogeneity within subgroups remained at a high level in a majority of the subgroup analyses (Table 1).
Jcm 11 00765 g002a 550Jcm 11 00765 g002b 550
Figure 1. Forest plots of risk estimates for the association between tuberculosis and lung cancer. (A) Meta-analysis of all eligible studies. (B) Meta-analysis of high-quality studies.
Jcm 11 00765 g003 550
Figure 2. Funnel plot of the study estimates. (A) All eligible studies. (B) High-quality studies.
Table 1. Meta-analysis of 33 eligible cohorts to assess the association between pulmonary tuberculosis and lung cancer.
Subgroup No. of Cohorts * OR (95% CI) p-Value I2 Value (%) I2 between
Subgroups (%)
 All cohorts 33 2.09 (1.62–2.69) <0.001 95  
 TB burden of country
   Low 18 1.77 (1.22–2.56) 0.003 97 12
   Medium 6 2.48 (1.71–3.58) <0.001 75
   High 9 2.57 (1.68–3.93) <0.001 81
 Region of country
   East Asia and Pacific 19 2.49 (1.83–3.39) <0.001 93 58
   Europe and Central Asia 7 1.60 (0.80–3.22) 0.185 98
   North America 7 1.53 (1.11–2.12) 0.010 0
 Economic status of country
   High-income 24 1.91 (1.41–2.59) <0.001 96 20
   Upper-middle-income 9 2.57 (1.68–3.93) <0.001 81
 Age
   Adjusted 29 2.00 (1.54–2.61) <0.001 95 14
   Not adjusted 4 3.84 (1.21–12.15) 0.022 82
 Sex
   Adjusted 22 2.23 (1.60–3.11) <0.001 96 0
   Not adjusted 11 1.90 (1.47–2.46) <0.001 61
 Smoking
   Adjusted 22 2.03 (1.51–2.73) <0.001 90 0
   Not adjusted 11 2.19 (1.34–3.59) 0.002 98
 Hypertension
   Adjusted 2 1.92 (0.66–5.57) 0.230 99 0
   Not adjusted 31 2.10 (1.62–2.73) <0.001 92
 Diabetes
   Adjusted 2 1.72 (0.48–6.20) 0.404 99 0
   Not adjusted 31 2.13 (1.63–2.77) <0.001 94
 Respiratory comorbidities
   Adjusted 8 1.32 (0.93–1.86) 0.121 94 90
   Not adjusted 25 2.51 (2.04–3.08) <0.001 78
 Cohort of the study
   Population-based 23 1.95 (1.41–2.68) <0.001 96 0
   Hospital-based 10 2.36 (1.85–3.01) <0.001 49
 Study design
   Prospective cohort study 4 1.96 (1.22–3.15) 0.005 84 94
   Retrospective cohort study 2 3.95 (3.58–4.36) <0.001 0
   Case-control study 27 1.99 (1.56–2.53) <0.001 89
 Diagnostic method
 of pulmonary TB
   Medical record 8 2.26 (1.29–3.94) 0.004 99 0
   Imaging 3 2.13 (1.16–3.92) 0.015 80
   Self-report or
   physical examination		 22 1.96 (1.56–2.47) <0.001 66

* Since two separate cohorts were reported in one article, a total of 33 eligible cohorts were extracted and analyzed from 32 enrolled studies. Abbreviations: CI, confidence interval; No, Number; OR, odds ratio; TB, tuberculosis.

3. Pulmonary TB and Risk of Lung Cancer with High-Quality Studies

The analysis of eight high-quality studies showed a higher OR (2.26, 95% CI: 1.29–3.94, p = 0.004) than the analysis of all the studies. There was a high heterogeneity (I2 = 99%) with no publication bias, with Egger p = 0.621, and no visual asymmetry in the funnel plot (Figure 1B and Figure 2B). Of the eight articles, seven had cohorts from countries with a low TB burden, and only one had a cohort from a country with a medium TB burden. In the subgroup analysis with a TB burden, the medium-burden countries showed higher OR (4.18, 95% CI: 3.15–5.55, p < 0.001) than the low-burden countries (OR: 2.04, 95% CI: 1.12–3.73, p = 0.020). Geographically, the East Asia and the Pacific region showed a more prominent risk (OR: 2.79, 95% CI: 1.21–6.39, p = 0.016) compared to the Europe and Central Asia regions (OR: 1.79, 95% CI: 0.67–4.77, p = 0.244) (Table 2).
Table 2. Meta-analysis of high-quality studies to assess the association between TB and lung cancer.
Subgroup No. of Studies OR (95% CI) p-Value I2 Value (%) I2 between
Subgroups (%)
 All studies 8 2.26 (1.29–3.94) 0.004 99  
 Country of TB burden          
   Low 7 2.04 (1.12–3.73) 0.020 99 78
   Medium 1 4.18 (3.15–5.55) <0.001 -
   High 0 - - -
 Region of country          
   East Asia and Pacific 4 2.79 (1.21–6.39) 0.016 98 0
   Europe and Central Asia 4 1.79 (0.67–4.77) 0.244 99
   North America 0 - - -

Abbreviations: CI, confidence interval; No, Number; OR, odds ratio; TB, tuberculosis.

4. Stratified and Sensitivity Analysis

The quality of the 33 included articles was evaluated using the NOS. The quality assessment of 27 case–control studies is shown in Table 3 and that of six retrospective cohort studies is demonstrated in Table 4. Meta-regression analyses were performed with continuous variables, such as the mean age at diagnosis of pulmonary TB, baseline characteristics including comorbidity, and pathological cell type of lung cancer.  Of these, patients with a low mean age at diagnosis of pulmonary TB showed a significant association between pulmonary TB and lung cancer. The primary analysis with all 32 articles estimated a regression coefficient of 0.949 (p < 0.001). The secondary analysis with eight high-quality studies with stringent TB diagnostic methods showed similar results (regression coefficient = 0.945, p < 0.001) (Figure 3).
Jcm 11 00765 g004a 550Jcm 11 00765 g004b 550
Figure 3. Meta-regression analysis of the mean patient age and association between tuberculosis and lung cancer. (A) All eligible studies. (B) High-quality studies.
Table 3. Quality assessment of the included case–control studies using the Newcastle–Ottawa Scale.
Study Selection Comparability Outcome Quality Score
Adequacy of Case Definition Degree of Representation of Cases Selection of Controls Definition of Controls Comparability of Cases and Controls on the Basis of Design or Analysis Confirmation of Exposure Same Method of Confirmation for Cases and Controls Non-Response Rate
An et al. 2020 [5] * * * * ** * * * 9
Yang et al. 2015 [6] * * * * **   * * 8
Yang et al. 2015 [7] * * * * * * * * 8
Hosgood et al. 2013 [8] * * * * *   * * 7
Lo et al. 2013 [9] * * * * **   * * 8
Bodmer et al. 2012 [10] * * * * ** * * * 9
Koshiol et al. 2010 [11] * * * * **   * * 8
Park et al. 2010 [12] * * * * **   *   7
Liang et al. 2009 [13] * * * * **   * * 8
Wang et al. 2009 [14] * * * * *   * * 7
Galeone et al. 2008 [15] * * * * **   * * 8
Ramanakumar et al. 2006 [16] a * * * * **   * * 8
Ramanakumar et al. 2006 [16] b * * * * **   * * 8
Zatloukal et al. 2003 [17] * * * * **   * * 8
Chan-Yeung et al. 2003 [18] * * * * *   * * 7
Kreuzer et al. 2002 [19] * * * * *   * * 7
Brenner et al. 2001 [20] * * * * **   * * 8
Kreuzer et al. 2001 [21] * * * * * * * * 8
Zhou et al. 2000 [22] * * * * *   * * 7
Osann et al. 2000 [23] * * * * **   * * 8
Mayne et al. 1999 [24] * * * * *   * * 7
Ko et al. 1997 [25] * * * *   * * * 7
Schwartz et al. 1996 [26] * * * * **   * * 8
Luo et al. 1996 [27] * * * * *   * * 7
Wu et al. 1995 [28] * * * * **   * * 8
Alavanja et al. 1992 [29] * * * * **   * * 8
Wu-Williams et al. 1990 [30] * * * * **   * * 8
a,b: Two separate cohorts reported in one article. Study a was conducted in 1979–1986 (755 cases and 512 controls); study b was conducted in 1996–2001 (1205 cases and 1541 controls). A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.
Table 4. Quality assessment of the included retrospective cohort studies using the Newcastle–Ottawa Scale.
  Selection Comparability Outcome Quality
Score
Study Degree of Representation of the Exposed Cohort Selection of the Non-Exposed Cohort Confirmation of Exposure Demonstration That the Current Outcome of Interest Is Absent at the Start of the Study Comparability of Cohorts Based on Design or Analysis Assessment of Outcome Sufficiency of Follow-Up to Detect Outcomes Adequacy of Follow-Up of Cohorts
Kim et al. 2020 [31] * *   * ** * *   7
Oh et al. 2020 [32] * *   * ** * * * 8
Simonsen et al. 2014 [33] * * * * * * * * 8
Bae et al. 2013 [34] * *   * ** * *   7
Shiels et al. 2011 [35] * * * * ** * * * 9
Yu et al. 2011 [36] * * * * * * *   7

It can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

This entry is adapted from the peer-reviewed paper 10.3390/jcm11030765

References

  1. Coussens, L.M.; Werb, Z. Inflammation and Cancer. Nature 2002, 420, 860–867.
  2. Brenner, D.R.; Boffetta, P.; Duell, E.J.; Bickeböller, H.; Rosenberger, A.; McCormack, V.; Muscat, J.E.; Yang, P.; Wichmann, H.-E.; Brueske-Hohlfeld, I.; et al. Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis From the International Lung Cancer Consortium. Am. J. Epidemiol. 2012, 176, 573–585.
  3. Brenner, D.R.; McLaughlin, J.R.; Hung, R.J. Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLoS ONE 2011, 6, e17479.
  4. Leung, C.Y.; Huang, H.-L.; Rahman, M.; Nomura, S.; Abe, S.K.; Saito, E.; Shibuya, K. Cancer Incidence Attributable to Tuberculosis in 2015: Global, Regional, and National Estimates. BMC Cancer 2020, 20, 1–13.
  5. An, S.J.; Kim, Y.J.; Han, S.S.; Heo, J. Effects of Age on the Association between Pulmonary Tuberculosis and Lung Cancer in a South Korean Cohort. J. Thorac. Dis. 2020, 12, 375–382.
  6. Yang, L.; Lu, X.; Deng, J.; Zhou, Y.; Huang, N.; Qiu, F.; Yang, X.; Yang, R.; Fang, W.; Ran, P.; et al. Risk Factors Shared by COPD and Lung Cancer and Mediation Effect of COPD: Two Center Case–Control Studies. Cancer Causes Control 2014, 26, 11–24.
  7. Yang, T.-Y.; Lin, W.-M.; Lin, C.-L.; Sung, F.-C.; Kao, C.-H. Correlation between Use of Simvastatin and Lovastatin and Female Lung Cancer Risk: A Nationwide Case-Control Study. Int. J. Clin. Pract. 2014, 69, 571–576.
  8. HosgoodIII, H.D.; Chapman, R.S.; He, X.; Hu, W.; Tian, L.; Liu, L.Z.; Lai, H.; Chen, W.; Rothman, N.; Lan, Q. History of Lung Disease and Risk of Lung Cancer in a Population with High Household Fuel Combustion Exposures in Rural China. Lung Cancer 2013, 81, 343–346.
  9. Lo, Y.-L.; Hsiao, C.-F.; Chang, G.-C.; Tsai, Y.-H.; Huang, M.-S.; Su, W.-C.; Chen, Y.-M.; Hsin, C.-W.; Chang, C.-H.; Yang, P.-C.; et al. Risk Factors for Primary Lung Cancer among Never Smokers by Gender in a Matched Case–Control Study. Cancer Causes Control 2012, 24, 567–576.
  10. Bodmer, M.; Becker, C.; Jick, S.S.; Meier, C.R. Metformin Does Not Alter the Risk of Lung Cancer: A Case–Control Analysis. Lung Cancer 2012, 78, 133–137.
  11. Koshiol, J.; Rotunno, M.; Consonni, D.; Pesatori, A.C.; De Matteis, S.; Goldstein, A.M.; Chaturvedi, A.K.; Wacholder, S.; Landi, M.T.; Lubin, J.H.; et al. Lower Risk of Lung Cancer after Multiple Pneumonia Diagnoses. Cancer Epidemiol. Biomark. Prev. 2010, 19, 716–721.
  12. Park, S.K.; Cho, L.Y.; Yang, J.J.; Park, B.; Chang, S.H.; Lee, K.S.; Kim, H.; Yoo, K.Y.; Lee, C.T. Lung Cancer Risk and Cigarette Smoking, Lung Tuberculosis According to Histologic Type and Gender in a Population Based Case-Control Study. Lung Cancer 2010, 68, 20–26.
  13. Liang, H.; Guan, P.; Yin, Z.; Li, X.; He, Q.; Zhou, B. Risk of Lung Cancer following Nonmalignant Respiratory Conditions among Nonsmoking Women Living in Shenyang, Northeast China. J. Womens Health 2009, 18, 1989–1995.
  14. Wang, X.R.; Yu, I.T.; Chiu, Y.L.; Qiu, H.; Fu, Z.; Goggins, W.; Au, J.S.; Tse, L.A.; Wong, T.W. Previous Pulmonary Disease and Family Cancer History Increase the Risk of Lung Cancer among Hong Kong Women. Cancer Causes Control 2009, 20, 757–763.
  15. Galeone, C.; Pelucchi, C.; La Vecchia, C.; Negri, E.; Bosetti, C.; Hu, J. Indoor Air Pollution from Solid Fuel Use, Chronic Lung Diseases and Lung Cancer in Harbin, Northeast China. Eur. J. Cancer Prev. 2008, 17, 473–478.
  16. Ramanakumar, A.V.; Parent, M.E.; Menzies, D.; Siemiatycki, J. Risk of Lung Cancer Following Nonmalignant Respiratory Conditions: Evidence from Two Case-Control Studies in Montreal, Canada. Lung Cancer 2006, 53, 5–12.
  17. Zatloukal, P.; Kubík, A.; Pauk, N.; Tomásek, L.; Petruzelka, L. Adenocarcinoma of the Lung among Women: Risk Associated with Smoking, Prior Lung Disease, Diet and Menstrual and Pregnancy History. Lung Cancer 2003, 41, 283–293.
  18. Chan-Yeung, M.; Koo, L.C.; Ho, J.C.; Tsang, K.W.; Chau, W.S.; Chiu, S.W.; Ip, M.S.; Lam, W.K. Risk Factors Associated with Lung Cancer in Hong Kong. Lung Cancer 2003, 40, 131–140.
  19. Kreuzer, M.; Heinrich, J.; Kreienbrock, L.; Rosario, A.S.; Gerken, M.; Wichmann, H.E. Risk Factors for Lung Cancer among Nonsmoking Women. Int. J. Cancer 2002, 100, 706–713.
  20. Brenner, A.V.; Wang, Z.; Kleinerman, R.A.; Wang, L.; Zhang, S.; Metayer, C.; Chen, K.; Lei, S.; Cui, H.; Lubin, J.H. Previous Pulmonary Diseases and Risk of Lung Cancer in Gansu Province, China. Int. J. Epidemiol. 2001, 30, 118–124.
  21. Kreuzer, M.; Gerken, M.; Kreienbrock, L.; Wellmann, J.; Wichmann, H.E. Lung Cancer in Lifetime Nonsmoking Men-Results of a Case-Control Study in Germany. Br. J. Cancer 2001, 84, 134–140.
  22. Zhou, B.S.; Wang, T.J.; Guan, P.; Wu, J.M. Indoor Air Pollution and Pulmonary Adenocarcinoma among Females: A Case-Control Study in Shenyang, China. Oncol. Rep. 2000, 7, 1253–1259.
  23. Osann, K.E.; Lowery, J.T.; Schell, M.J. Small Cell Lung Cancer in Women: Risk Associated with Smoking, Prior Respiratory Disease, and Occupation. Lung Cancer 2000, 28, 1–10.
  24. Mayne, S.T.; Buenconsejo, J.; Janerich, D.T. Previous Lung Disease and Risk of Lung Cancer among Men and Women Nonsmokers. Am. J. Epidemiol. 1999, 149, 13–20.
  25. Ko, Y.C.; Lee, C.H.; Chen, M.J.; Huang, C.C.; Chang, W.Y.; Lin, H.J.; Wang, H.Z.; Chang, P.Y. Risk Factors for Primary Lung Cancer among Non-Smoking Women in Taiwan. Int. J. Epidemiol. 1997, 26, 24–31.
  26. Schwartz, A.G.; Yang, P.; Swanson, G.M. Familial Risk of Lung Cancer among Nonsmokers and their Relatives. Am. J. Epidemiol. 1996, 144, 554–562.
  27. Luo, R.X.; Wu, B.; Yi, Y.N.; Huang, Z.W.; Lin, R.T. Indoor Burning Coal Air Pollution and Lung Cancer—A Case-Control Study in Fuzhou, China. Lung Cancer 1996, 14 (Suppl. 1), S113–S119.
  28. Wu, A.H.; Fontham, E.T.; Reynolds, P.; Greenberg, R.S.; Buffler, P.; Liff, J.; Boyd, P.; Henderson, B.E.; Correa, P. Previous Lung Disease and Risk of Lung Cancer among Lifetime Nonsmoking Women in the United States. Am. J. Epidemiol. 1995, 141, 1023–1032.
  29. Alavanja, M.C.; Brownson, R.C.; Boice, J.D., Jr.; Hock, E. Preexisting Lung Disease and Lung Cancer among Nonsmoking Women. Am. J. Epidemiol. 1992, 136, 623–632.
  30. Wu-Williams, A.H.; Dai, X.D.; Blot, W.; Xu, Z.Y.; Sun, X.W.; Xiao, H.P.; Stone, B.J.; Yu, S.F.; Feng, Y.P.; Ershow, A.G.; et al. Lung Cancer among Women in North-East China. Br. J. Cancer 1990, 62, 982–987.
  31. Kim, H.; Kim, H.Y.; Goo, J.M.; Kim, Y. Lung Cancer CT Screening and Lung-Rads in a Tuberculosis-Endemic Country: The Korean Lung Cancer Screening Project (K-LUCAS). Radiology 2020, 296, 181–188.
  32. Oh, C.-M.; Roh, Y.-H.; Lim, D.; Kong, H.-J.; Cho, H.; Hwangbo, B.; Won, Y.-J.; Jung, K.-W.; Oh, K. Pulmonary Tuberculosis is Associated with Elevated Risk of Lung Cancer in Korea: The Nationwide Cohort Study. J. Cancer 2020, 11, 1899–1906.
  33. Simonsen, D.F.; Farkas, D.K.; Søgaard, M.; Horsburgh, C.R.; Sørensen, H.T.; Thomsen, R.W. Tuberculosis and Risk of Cancer: A Danish Nationwide Cohort Study. Int. J. Tuberc. Lung Dis. 2014, 18, 1211–1219.
  34. Bae, J.-M.; Li, Z.-M.; Shin, M.-H.; Kim, D.-H.; Lee, M.-S.; Ahn, Y.-O. Pulmonary Tuberculosis and Lung Cancer Risk in Current Smokers: The Seoul Male Cancer Cohort Study. J. Korean Med. Sci. 2013, 28, 896–900.
  35. Shiels, M.S.; Albanes, D.; Virtamo, J.; Engels, E.A. Increased Risk of Lung Cancer in Men with Tuberculosis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol. Biomark. Prev. 2011, 20, 672–678.
  36. Yu, Y.H.; Liao, C.C.; Hsu, W.H.; Chen, H.J.; Liao, W.C.; Muo, C.H.; Sung, F.C.; Chen, C.Y. Increased Lung Cancer Risk among Patients with Pulmonary Tuberculosis: A Population Cohort study. J. Thorac. Oncol. 2011, 6, 32–37.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback